Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
Operator of a biopharmaceutical company intended to develop vaccines against infectious diseases. The company offers an end-to-end outsourcing opportunity that includes QC assays, batch records, a full set of documentation and in-person training that helps in contract manufacturing and development services and also provides a fully equipped quality control lab for identity, potency, purity and stability testing, enabling clients to overcome health inequalities and empower people to live healthy lives.
Brightseed, Inc. is a biotechnology company that specializes in discovering clinically beneficial molecules found in plants through its innovative Forager platform. Founded in 2017 and based in San Francisco, California, the company employs artificial intelligence and machine learning algorithms to screen plant genes, identifying the most effective sources for addressing various health conditions. By uncovering naturally occurring compounds with potential health benefits, Brightseed aims to enhance the quality of life and support chronic disease management. The company’s mission is to strengthen the connection between people and plants, ultimately facilitating a healthier future for individuals and communities.
Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.
Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, that focuses on developing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across all stages of life, with particular emphasis on supporting the microbiome of newborn infants. Evolve Biosystems offers both consumer-directed home use products and hospital-based solutions for neonatal intensive care units. With a discovery platform that also addresses microbiome issues in production animals, the company aims to meet various unmet clinical needs. Founded in 2011, Evolve Biosystems is committed to advancing microbiome health through innovative probiotic solutions.
Scripps Research is a leading not-for-profit organization dedicated to advancing biomedical research and education to enhance human health. Established in 1924, it originated from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps. The institute is recognized globally for its significant contributions to health science, including the development of treatments for cancer, rheumatoid arthritis, and hemophilia. With approximately 3,000 employees across its campuses in La Jolla, California, and Jupiter, Florida, Scripps Research is home to renowned scientists, including three Nobel laureates, who are engaged in groundbreaking discoveries. Additionally, its graduate program in biology and chemistry is consistently ranked among the top ten in the United States, reflecting the institute's commitment to education and innovation in the biomedical sciences.
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a range of products that includes lactoferrin and lysozyme glycoproteins, which are utilized for gastrointestinal health and the dietary management of acute diarrhea, as well as for treating topical infections and fungal conditions. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and operates a BioShare program that grants researchers access to recombinant proteins and peptides for various research applications. The company leverages its patented ExpressTec technology, which enhances recombinant protein yield through a plant-based manufacturing process, enabling the development of new biotherapeutics, vaccines, and other biomanufacturing reagents.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
Mologic Ltd. is a diagnostic product developer based in Thurleigh, United Kingdom, founded in 2003. The company specializes in creating innovative solutions for the research market, focusing on areas such as clinical research, diagnostic development, and microbial physiology. Mologic offers a range of products, including lateral flow kits for human Alpha-1 antitrypsin, desmosine ELISA kits for urine assays, and the fMLP assay kit for measuring fMLP in human urine. In addition to its product lineup, Mologic provides services such as assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies targeting challenging biological entities. The company was established by Paul and Mark Davis, driven by a mission to enhance healthcare and education, thereby improving patient care and quality of life.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
Batavia Biosciences is a biotechnology company that specializes in accelerating the development of biopharmaceutical products, including viral and bacterial vaccines, recombinant proteins, antibodies, and gene therapy products. The company offers a comprehensive range of services that encompass candidate selection, production of research materials, and both upstream and downstream process development. Additionally, Batavia Biosciences provides assay development, product characterization, and clinical manufacturing. By leveraging unique technologies such as STEP® protein expression technology and SCOUT® high throughput process technology, the company aims to enhance the efficiency and cost-effectiveness of the early stages of product development. This focus allows Batavia Biosciences to help clients complete their preclinical phases more quickly while improving the likelihood of success in transitioning to clinical trials.
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is the kind of place where the big news doesn't always involve sports, politics, fashion or even weather. The big news is always about health — health care, health education, health-related research. And various organizations and publications that rank American institutions, programs and faculty in a variety of categories have taken note. Nearly one million patient visits each year. Educating thousands of future health care providers. You get the picture. Immerse yourself in more facts and stats than you probably need about Portland's largest employer, Oregon's provider of care to every corner of the state, and one of the nation's top 28 biomedical research institutions. Oregon Health & Science University is the state’s only academic health center. It provides an uncommon array of services from providing the state’s most comprehensive health care, to educating the next generation of clinicians and biomedical researchers, to achieving breakthroughs and innovations.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.